Commentary on Braga et al
| Autor: | William V. McCall, Worrawat Chanpattana |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
endocrine system
animal structures Psychotherapist medicine.medical_treatment Neuroscience (miscellaneous) MEDLINE Pilot Projects behavioral disciplines and activities 03 medical and health sciences 0302 clinical medicine Electroconvulsive therapy mental disorders Humans Medicine Combined Modality Therapy Electroconvulsive Therapy Clozapine business.industry medicine.disease 030227 psychiatry Psychiatry and Mental health Schizophrenia Treatment resistant schizophrenia business hormones hormone substitutes and hormone antagonists 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | The Journal of ECT. 35:153-155 |
| ISSN: | 1533-4112 1095-0680 |
| DOI: | 10.1097/yct.0000000000000584 |
| Popis: | This commentary reflects upon the study of Braga et al of open-label continuation electroconvulsive therapy (ECT) plus clozapine in treatment-resistant schizophrenia (TRS), as reported in this issue of The Journal of ECT. The evidence base for ECT in TRS is scant, and the study of Braga et al is a step forward. However, their report raises other important questions including (1) what is the proper frequency of continuation ECT in TRS, and (2) should TRS patients, even TRS patients who have failed clozapine, receive acute ECT + clozapine, or is ECT + conventional antipsychotics sufficient? In this commentary, we examine these questions and outline a future research strategy for TRS that includes large simple trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|